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Abstract: We have investigated the regulation of genes and associated molecular pathways,
genome-wide, in oral cells of electronic cigarette (e-cigs) users and cigarette smokers as compared to
non-smokers. Interrogation of the oral transcriptome by RNA-sequencing (RNA-seq) analysis showed
significant number of aberrantly expressed transcripts in both e-cig users (vapers) and smokers
relative to non-smokers; however, smokers had ~50% more differentially expressed transcripts than
vapers (1726 versus 1152). Whereas the deregulated transcripts in smokers were predominately from
protein-coding genes (79% versus 53% in vapers), nearly 28% of the aberrantly expressed transcripts
in vapers (versus 8% in smokers) belonged to regulatory non-coding RNAs, including long intergenic
non-coding, antisense, small nucleolar and misc RNA (P < 0.0001). Molecular pathway and functional
network analyses revealed that “cancer” was the top disease associated with the deregulated genes
in both e-cig users and smokers (~62% versus 79%). Examination of the canonical pathways and
networks modulated in either e-cig users or smokers identified the “Wnt/Ca+ pathway” in vapers
and the “integrin signaling pathway” in smokers as the most affected pathways. Amongst the
overlapping functional pathways impacted in both e-cig users and smokers, the “Rho family GTPases
signaling pathway” was the top disrupted pathway, although the number of affected targets was
three times higher in smokers than vapers. In conclusion, we observed deregulation of critically
important genes and associated molecular pathways in the oral epithelium of vapers that bears both
resemblances and differences with that of smokers. Our findings have significant implications for
public health and tobacco regulatory science.
Keywords: carcinogenesis; gene regulation; transcription; RNA-seq; vaping
1. Introduction
Electronic cigarettes (e-cigs) are battery-powered handheld devices that simulate tobacco
smoking [1]. E-cigs heat a solution (i.e., e-liquid/e-juice) containing a mixture of propylene glycol,
vegetable glycerin, concentrated flavors, and optionally, variable concentrations of nicotine into
inhalable vapor [2]. E-cig use is commonly referred to as “vaping”, and e-cig users are interchangeably
termed “vapers” [3]. E-cigs were introduced into the US market over a decade ago as a putatively
less-harmful tobacco substitute [1]. Over the past several years, the appeal and popularity of e-cigs
have significantly increased as evidenced by the nearly 10-fold rise in the prevalence of vaping,
especially among adult smokers [4] and adolescent never smokers [5]. Meanwhile, the number and
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type of e-cig products have increased exponentially, albeit little or no systematic regulation of sales
has been in place [1]. In 2013–2014, 5.5% of the US adult population were the current e-cig users then,
representing over 13 million people [4]. Although recent trends suggested decreasing past-month’s use
of e-cigs by adolescents, the use of e-cigs in this population exceeded that of conventional cigarettes in
2015, 2016, and 2017 [6]. Furthermore, US retail sales for e-cigs have consistently increased in the past
several years, and are expected to surpass those of combustible cigarettes by year 2023 [1,3].
E-cig use is a pressing public health concern in many parts of the world [1]. This is due to
the uncertainties surrounding the potential health consequences of vaping and its effectiveness as
a putative tobacco harm-reduction strategy [3]. Currently, there is a paucity of data on e-cig safety,
and very limited scientific evidence to support the efficacy of vaping in aiding smoking cessation [1].
There is also a concern that e-cig use may lead to nicotine addiction and smoking, especially among
youth [7,8]. The existing data show that e-cig vapor is not merely “water vapor” as is often claimed
in alluring advertisements and marketing campaigns [2]. Chemical analyses of e-cig vapor and
liquid have confirmed the presence of many toxicants and carcinogens as those found in cigarette
smoke [1–3,9]. Although the concentrations of most carcinogenic compounds in e-cig products are
much lower than those in cigarette smoke, there is no “safe” level of exposure to carcinogens [3]. Thus,
lower levels of carcinogens in e-cig products do not equate to no cancer risk. It is, therefore, important
to investigate whether e-cig-derived carcinogens pose a cancer risk to regular vapers and/or to those
who are involuntarily exposed to e-cig contaminants in the environment. Equally important is to
determine the magnitude of cancer risk associated with vaping as compared to smoking.
Human cancer is characterized by deregulation of genes involved in crucial cellular functions,
such as growth control and differentiation [10,11]. Investigating the global expression of genes
and associated molecular pathways and gene networks in tissues or organs of humans exposed
to carcinogens can provide insights into the biological consequences of exposure to carcinogenic
compounds. Consistent with tobacco smoking being a major risk factor for various types of
human cancer, deregulation of cancer-related genes and disruption of associated pathways and
networks have been demonstrated in target and relevant surrogate tissues of cigarette smokers [12–15].
To date, however, the impact of e-cig use on gene regulation has not been investigated in regular
vapers. In the present study, we have determined the effects of vaping versus smoking on gene
regulation by interrogating the oral transcriptome in exclusive e-cig users and cigarette smokers
as compared to non-smokers. The choice of oral epithelial cells to evaluate the cancer-causing
potential of vaping versus smoking is highly relevant because oral epithelium is a major target
tissue for smoking-associated cancer [16,17]. Here, we have used a validated non-invasive brushing
technique [18] to obtain oral epithelial cells from three groups of healthy adults, including exclusive
e-cig users, cigarette smokers only, and non-smokers (n = 42, 24, and 27, respectively). We have
performed whole transcriptome analysis on total RNA isolated from oral cells of the study subjects
using RNA-sequencing (RNA-seq) technology. Furthermore, we have performed gene ontology
analysis on the identified differentially expressed genes in e-cig users and smokers using a combination
of bioinformatics resources and tools. Finally, we have validated the results, at single gene level, using
reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis.
2. Results
2.1. Genome-Wide Gene-Expression Analysis
To investigate the impact of vaping versus smoking on the whole transcriptome, we performed
RNA-seq analysis on total RNA isolated from oral cells of e-cig users and cigarette smokers in
comparison to controls, i.e., non-smokers non-vapers. As shown in Figure 1a, there were large
numbers of differentially expressed transcripts in both e-cig users and cigarette smokers relative
to controls (>1.5 fold-change and P < 0.005), although, smokers had nearly 50% more aberrantly
expressed transcripts than e-cig users (1726 versus 1152). There were 857 up-regulated transcripts and
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295 down-regulated transcripts in e-cig users, corresponding to 74.4% and 25.6% of all differentially
expressed transcripts in this group. The corresponding numbers of over-expressed and under
expressed transcripts in smokers were 1383 and 343, representing 80.1% and 19.9%, respectively,
of all their differentially expressed transcripts. Compiled lists of aberrantly expressed transcripts
and associated genomic loci (if annotated) in the e-cig users and cigarette smokers are provided in
Supplementary Tables S1 and S2, respectively.
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Figure 1. Aberrantly expressed transcripts d y RNA-sequencing (RNA-seq) in electronic
cigarette (e-cig) users and s as compared to c ntrols. (a) Numbe s of up-regulated and
down-regulated transcripts in e-cig users and smokers are indicated. Fold-change: >1.5; P < 0.005.
(b) Venn diagram of deregulated transcripts in e-cig users and smokers is shown.
The differentially expressed transcripts in e-cig users and smokers can be classified into three
categories: (I) vape-specific: transcripts exclusively deregulated in e-cig users; (II) smoke-specific:
transcripts exclusively deregulated in smokers; and (III) common to vape and smoke: transcripts
deregulated in both e-cig users and smokers (Figure 1b). Whereas the vape-specific transcripts
comprised 74.1% of all differentially expressed transcripts in e-cig users, smoke-specific transcripts
constituted 82.7% of all aberrantly expressed transcripts in cigarette smokers. The commonly
deregulated transcripts i e-cig users and smokers comprised 25.9% and 17.3% of all differentially
expressed transcripts in the respective groups.
Altogether, these data indicate that e-cig users have significant over-expression and under
expression of genes in oral epithelium, which is a major target site for smoking-associated
carcinogenesis [16,17]. The aberrantly expressed transcripts detected in e-cig users are partly
overlapping with but mostly different from those found in smokers.
2.2. Gene Ontology an Molecular Pathway and Fu ctional Network Analyses
We next used a combination of the Ingenuity Pathway Analysis® (IPA® v. 9.0) and the gene
ontology (GO) functional a notation clustering analysis (Database f r Annotation, Visualization and
Integrated Discovery (DAVID) v. 6.8) to obtain a detailed ge e o tology information on the g ne lists
generated by RNA-s q in e-cig users and smokers as compared to controls. Of the 1152 ab rrantly
expressed transcripts in e-cig users, 876 (76%) mapped to known IDs in the IPA database, whereas
1539 out of 1726 deregulated transcripts in smokers (89%) had an assigned ID. As shown in Figure 2,
cancer was the top listed disease associated with the deregulated targets in both e-cig users (543
out of 876 identified transcripts: ~62%) and smokers (1222 out of 1539 identified transcripts: ~79%).
Of significance, only 53% of the aberrantly transcribed DNA sequences in e-cig users versus 79%
in smokers were protein-coding (P < 0.0001) (Figure 3). On the other hand, nearly 28% of the
aberrant transcripts detected in e-cig users belonged to diverse classes of regulatory non-coding
RNAs, including long intergenic non-coding (linc), antisense, small nucleolar (sno), and misc RNA
(Figure 3). In smokers, however, a much smaller percentage of differentially expressed transcripts
(~8%) consisted of regulatory non-coding RNAs (P < 0.0001) (Figure 3).
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Figure 2. Functional pathway analysis of differentially expressed genes in e-cig users and smokers
relative to controls by IPA®. In both groups, differentially expressed genes are predominantly associated
with “cancer”. The “Wnt/Ca+ pathway” in e-cig users and the “integrin signaling pathway” in smokers
are the most affected pathways.
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To further compare and contrast the molecular effects associated with vaping and smoking,
we examined the canonical pathways and networks that were modulated in either e-cig users or
smokers. We found that the most affected pathway in e-cig users was the “Wnt/Ca+ pathway” (P = 4.7
× 10−5), while in smokers the “integrin signaling pathway” was primarily impacted (P = 1.42 ×
10−8) (Figure 2). To explore possible commonalities between the biological effects of vaping and
smoking, we also examined the overlapping functional pathways that were compromised in both
e-cig users and smokers as compared to non-users. The heatmap generated by Comparison Analysis
in IPA summarizes all the significant signaling cascades detected across the two datasets (Figure 4a).
As shown in Figure 4a, the “Rho family GTPases signaling pathway” is the top deregulated pathway
in both vapers and smokers, although the number of affected targets is three times higher in smokers
than vapers (27 versus 9). The Molecule Activity Predictor (MAP) tool was used to predict how the
up-regulated and down-regulated genes in the datasets could affect the activity of other molecules
in the Rho family GTPases signaling cascade (Figure 4b). The Comparison Analysis in IPA was also
used to identify upstream regulators, including transcription factors and chemicals, whose activities
appeared to be affected in both e-cig users and smokers, at times with opposing effects (Figure S1).
Amongst the identified upstream regulators is the tumor suppressor p53 gene (TP53), which is the
most frequently mutated gene in head and neck squamous cell carcinoma-associated with smoking
(41%) [19] (Figure S2).
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Figure 4. Common canonical pathways disrupted in e-cig users and smokers relative to controls by
IPA®. (a) The canonical pathway heatmap visualizes the affected canonical pathways simultaneously
in e-cig users and smokers, allowing a direct comparison between the two groups. (b) Predicting
how up-regulated and down-regulated genes in the datasets (red and green nodes, respectively, on
the pathway) can affect the activity of other molecules on the pathway. Orange nodes, prediction of
activation; blue nodes, prediction of inhibition.
DAVID analysis of the datasets generated by RNA-seq in e-cig users and smokers confirmed
the gene ontology results obtained by IPA. Using Functional Annotation Clustering Enrichment
Int. J. Mol. Sci. 2019, 20, 738 6 of 18
Score in DAVID, we identified top clusters in e-cig users and smokers as compared to controls
(Figure 5). The most represented functional categories in e-cig users included molecules involved in
chaperones, stress response, and ATP-binding and Wnt-binding proteins. Of note, many of the DAVID
IDs identified in e-cig users are known to be specifically involved in tumorigenesis, particularly, in
smoking-related cancer, such as lung cancer, squamous cell carcinoma of the head and neck, esophageal
cancer, bladder cancer, ovarian cancer, and leukemia (see, Table S3). In smokers, the top functional
clusters included genes involved in keratinocyte differentiation, small GTPase superfamily, cell–cell
adhesion, and protein serine/threonine phosphatase activity (Figure 5).
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Figure 5. Gene ontology analysis of the differentially expressed genes in e-cig users and smokers
relative to controls by Database for Annotation, Visualization and Integrated Discovery (DAVID). The
top ten functional clusters in e-cig users and smokers are shown. Enrichment scores are indicated
in parentheses.
Altogether, our gene ontology analyses show that vapers, similarly to smokers, have deregulation
of key genes, the majority of which being cancer-related and potentially involved in the initiation
and/or promotion of tumorigenesis. Whilst the extent of gene deregulation in vapers differs from that
of smokers, the disrupted functional pathways and networks in the vapers are partly similar to, but
mostly different from those found in smokers.
2.3. Validation of Gene-Expression Data by Real-Time Reverse Transcription Quantitative PCR (RT-qPCR)
To independently validate the gene-expression data, we randomly selected several up- and
down-regulated targets identified by RNA-seq in the e-cig user and smoker groups, and examined
their transcription le els by RT-qPCR. Figure 6 h ws the median or alized xpres ion levels of
several aberrantly expressed transcripts initially detected by RNA-seq in the oral cells of e-cig users
and smokers, as compared to controls. In agreement with the RNA-sequencing results, we detected
down-regulation of two tumor suppressor genes, including NOTCH1 and HERC2 [20,21], in both
e-cig users and smokers (Figure 6). Furthermore, we verified up-regulation of the BCL2 associated
athanogene 3 (BAG3) gene and its binding partner, the heat shock protein 70 (HSPA1B), the protein
phosphatase 1 regulatory inhibitor subunit 14C (PPP1R14C), and abhydrolase domain containing 8
(ABHD8) in both e-cig users and smokers (Figure 6). In all cases, we observed statistically significant
correlations between expression levels of genes detected by RNA-seq and their corresponding
expression levels quantified by RT-qPCR (see Figure 6).
Altogeth r, we have confir ed deregulation of a number of gene targets initially identified
by RNA-s q analysis in e-c g users and smoker . More specifically, we observed a high degree of
Int. J. Mol. Sci. 2019, 20, 738 7 of 18
correlation between expression levels of aberrant transcripts detected by RNA-seq analysis and
their corresponding expression levels measured by RT-qPCR, which attests to the validity and
reproducibility of our whole transcriptome analysis.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 17 
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2.4. Verification of Smoking/Vaping Status
We measured the concentration of plasma cotinine, a prominent metabolite of nicotine [22],
in e-cig users and cigarette smokers in comparison to controls (i.e., non-smokers non-vapers) by
an enzyme-linked immunosorbent assay (ELISA). As shown in Table 1, smokers and vapers had
comparable levels of plasma nicotine, which were significantly higher than those in non-smokers
(P < 0.001). Measuring carbon monoxide (CO) levels in smokers’ breath provides an objective
Int. J. Mol. Sci. 2019, 20, 738 8 of 18
biomarker of recent exposure to tobacco smoke [23,24]. Therefore, we also measured CO levels
in exhaled breath from subgroups of e-cig users, smokers, and controls by a breath CO monitor.
Whereas smokers had significantly higher levels of breath CO as compared to controls (P < 0.00001),
e-cig users showed almost similar levels of breath CO to those of controls (Figure 7). The estimated
percentage of carboxyhemoglobin (%COHb), which is indicative of the proportion of red blood cells
carrying CO instead of oxygen [25], was significantly higher in smokers than controls (P < 0.00001).
Conversely, e-cig users and controls had approximately similar %COHb (Figure 7). Our measurements
of plasma cotinine and breath CO, and determination of %COHb were fully consistent with
smoking/vaping status of the study participants as reported in their questionnaires and personal
interviews. This reassures the validity of our screening tools to reliably determine the smoking/vaping
status of the study participants.
Table 1. Characteristics of the study population.
E-cig Users
(n = 42)
Smokers
(n = 24)
Controls
(n = 27)
Age * 28 ±1.3 42 ±2.8 24 ±1.7
Gender
Male 34(81.0%)
19
(79.2%)
16
(59.3%)
Female 8(19.0%)
5
(20.8%)
11
(40.7%)
Race
White 16(38.1%)
5
(20.8%)
5
(18.5%)
Hispanic 12(28.6%)
1
(4.2%)
5
(18.5%)
African American 5(11.9%)
9
(37.5%)
2
(7.4%)
Asian 7(16.7%)
4
(16.7%)
12
(44.4%)
Other 2(4.8%)
5
(20.8%)
3
(11.1%)
Education
Less than high school 0(0%)
3
(12.5%)
0
(0%)
High school diploma or GED 11(26.2%)
2
(8.3%)
0
(0%)
Some college completed or currently
enrolled in college
19
(45.2%)
8
(33.3%)
1
(3.7%)
College degree or higher 12(28.6%)
11
(45.8%)
26
(96.3%)
Marital status
Married 6(14.3%)
3
(12.5%)
0
(0%)
Currently living with someone 2(4.8%)
0
(0%)
0
(0%)
Widowed 1(2.4%)
0
(0%)
0
(0%)
Separated 1(2.4%)
1
(4.2%)
0
(0%)
Divorced 5(11.9%)
2
(8.3%)
3
(11.1%)
Single and never married 27(64.3%)
18
(75.0%)
24
(88.9%)
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Table 1. Cont.
E-cig Users
(n = 42)
Smokers
(n = 24)
Controls
(n = 27)
Employment status
Full time 26(61.9%)
12
(50%)
19
(70.4%)
Part time 9(21.4%)
4
(16.7%)
6
(22.2%)
Retired or disability 1(2.4%)
3
(12.5%)
0
(0%)
Unemployed 6(14.3%)
5
(20.8%)
2
(7.4%)
Pre-tax-annual
income
<$15,000 4(9.5%)
9
(37.5%)
9
(33.3%)
≥$15,000 to < $30,000 12(28.6%)
5
(20.8%)
5
(18.5%)
≥$30,000 to < $45,000 9(21.4%)
4
(16.7%)
4
(14.8%)
≥$45,000 to < $60,000 6(14.3%)
1
(4.2%)
2
(7.4%)
≥$60,000 to < $75,000 3(7.1%)
0
(0%)
2
(7.4%)
≥$75,000 to < $90,000 3(7.1%)
1
(4.2%)
1
(3.7%)
≥$90,000 to < $105,000 1(2.4%)
1
(4.2%)
1
(3.7%)
≥$105,000 to < $120,000 0(0%)
1
(4.2%)
0
(0%)
≥$120,000 4(9.5%)
2
(8.3%)
3
(11.1%)
BMI *,† 27.9 ± 1.1 27.2 ± 0.9 25.0 ± 1.3
Pack Year *,‡ NA 12.3 ± 2.5 NA
Cumulative e-liquid (mL) *,¶ 5369.5 ± 3038.5 NA NA
Cumulative e-nicotine (mg) *,¶¶ 20,859.7 ± 10,346.6 NA NA
Plasma cotinine (ng/mL) * 115.0 ± 8.5 122.0 ± 10.8 2.5 ± 0.1
* Results are expressed as Median ± SE. † BMI, body mass index (Weight (kg) ÷ Height2 (m)). ‡ In smokers, pack
year was calculated by multiplying the number of packs of cigarette a person smoked per day by the number
of years he/she smoked. ¶ In e-cig users, cumulative e-liquid was calculated as the total volume of e-liquid (in
milliliter) vaped by a person during his/her lifetime. ¶¶ In e-cig users, cumulative e-nicotine was calculated as
the total amount of nicotine (in milligrams) present in e-liquid vaped by a person during his/her lifetime. GED,
General Education Development or General Education Diploma; the GED or High School Equivalency Certificate
shows that one has a level of knowledge equivalent to a high school graduate. NA, not applicable.
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(n = 24) 
Controls 
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34 
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Figure 7. Validation of smoking/vaping status. Exhaled breath was measured in e-cig users, smokers,
and controls (n = 18, 25, and 30, respectively) by a Bedfont Micro+TM Smokerlyzer® Breath CO monitor
according to the instructions of the manufacturer (Bedfont Scientific Ltd., Kent, UK). Whisker box
plots display distributions of carbon monoxide (CO) levels (parts per million, ppm) and percentage of
carboxyhemoglobin (%COHb) in the respective groups.
3. Discussion
We have investigated the regulation of genes and associated molecular pathways, genome-wide,
in oral cells of exclusive e-cig users and cigarette smokers as compared to non-smokers. The use
of oral epithelial cells to evaluate the biological consequences of vaping versus smoking relevant to
cancer is significant due to the following reasons: (i) over 90% of all human cancers are of epithelial
origin [26]; (ii) oral epithelium is the first site of exposure to carcinogens present in both e-cig vapor
and cigarette smoke [27,28]; (iii) oral epithelial cells are a major target for tumor development and
other anomalies associated with tobacco use [16,17]; (iv) oral epithelium possesses xenobiotic enzymes
capable of converting proximate carcinogens to reactive metabolites [29,30]; (v) oral epithelial cells and
lung epithelial cells show striking similarities in response to tobacco carcinogens, as evidenced by the
comparable patterns of genotoxic [31–34] and transcriptomic effects [14,15,30,35,36] in oral cells and
lung cells, respectively, from smokers; and (vi) oral epithelial cells are readily available for sampling
by non-invasive techniques [36,37].
Interrogation of the whole transcriptome in oral cells of vapers and smokers as compared to
non-smokers by RNA-seq analysis identified significant number of aberrantly expressed transcripts in
both e-cig users and cigarette smokers, although, smokers had approximately 50% more differentially
expressed transcripts than vapers (1726 versus 1152; see Figure 1). We obtained a detailed gene
ontology information on the aberrantly expressed genes detected in e-cig users and smokers relative to
controls using a combination of bioinformatics resources and tools. As shown in Figure 2, “cancer”
was the top disease associated with the deregulated genes in both e-cig users and smokers (~62 versus
79%). Whereas the deregulated transcripts in smokers are predominately from protein-coding genes
(79 versus 53% in vapers; P < 0.0001), more than a quarter of the aberrantly expressed transcripts
in e-cig users belong to several classes of regulatory non-coding RNAs (Figure 3). An increasing
number of reports has documented the crucial role of non-coding RNAs in a variety of biological and
pathological processes. Among other things, functional non-coding RNAs are known to regulate the
expression of protein-coding genes, and are involved in the maintenance of genome integrity [38,39].
Of relevance to this study, several long non-coding and small nucleolar RNAs have been found to
be deregulated in head and neck squamous cell carcinoma [40,41], a cancer type strongly associated
with tobacco smoking [42]. It has been suggested that these regulatory non-coding RNAs may drive
malignant transformation by influencing cancer cell viability and motility [40,41].
Examination of the canonical pathways and networks that were modulated in either e-cig users or
smokers showed that two prominent signaling pathways, including the “Wnt/Ca+ pathway” in vapers
and the “integrin pathway” in smokers, were the most affected pathways (see Figure 2). The Wnt/Ca2+
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signaling pathway is less characterized than its canonical counterpart, the Wnt/β-catenin pathway [43].
Initially, the Wnt/Ca+ pathway was thought to play a unique role in development; however, there is
now substantial evidence that this signaling cascade is involved in many other molecular processes [43].
For instance, it has been shown that the Wnt/Ca+ signaling pathway, which is activated by the tumor
suppressor WNT5A in the presence of a “frizzled” class receptor, is down-regulated in several types
of cancer [43]. In the present study, the WNT5A gene and the frizzled receptor FDZ7 gene were
down-regulated in e-cig users, most likely causing inhibition of downstream effectors of the cascade
(Table S1). The top deregulated signaling pathway in smokers, the integrin signaling pathway, is
known to modulate cell proliferation, survival, and migration. When deregulated, this pathway can
promote tumor invasion and metastasis [44].
Amongst the overlapping functional pathways that were impacted in both e-cig users and
smokers, the “Rho family GTPases signaling pathway” was the top disrupted pathway in both vapers
and smokers, although the number of affected targets was three times greater in smokers than in
vapers. The GTPase family of small GTP-binding proteins comprises a group of signaling molecules
that are activated by growth factors, hormones, integrins, cytokines, and adhesion molecules [45].
They regulate a wide range of biological processes, including reorganization of the actin cytoskeleton,
transcriptional regulation, vesicle trafficking, morphogenesis, neutrophil activation, phagocytosis,
mitogenesis, apoptosis, and tumorigenesis. One major function attributed to Rho GTPases is the
organization of the actin cytoskeleton, with the formation of actin stress fibers and focal adhesion
complexes. In addition, Rho GTPases may play a role in the DNA damage response following
genotoxin treatment [45]. Recently, it has been proposed that these GTPases regulate structures of the
nuclear cytoskeleton, assuring the temporal and spatial distribution of DNA repair factors at the site of
damage [45].
We independently validated the RNA-seq data by performing RT-qPCR analysis on randomly
selected deregulated genes identified by whole transcriptome analysis. Consistent with
RNA-sequencing results, we verified down-regulation of two tumor suppressor genes, including
NOTCH1 and HERC2 [20,21], in both e-cig users and smokers (Figure 6). The NOTCH signaling
pathway regulates the fates of segregating daughter cells during asymmetric cell division, and plays
a crucial role in the maintenance of the adult oral squamous epithelium [20]. Reduced expression
of NOTCH1 has been detected by immunohistochemistry not only in oral squamous cell carcinoma
but also in oral epithelial dysplasia, suggesting that deregulation of NOTCH1 is an early event in the
disease [20]. Of relevance, loss-of-function mutations of the NOTCH1 gene have been detected in
about 10% of head and neck squamous cell carcinoma (HNSCC), making it one of the most mutated
genes in squamous cell carcinoma, which is highly associated with smoking [19,46]. Moreover, we
confirmed down-regulation of the HECT and RLD domain containing E3 ubiquitin ligase (HERC2) in
e-cig users and smokers as compared to controls. The best characterized functions of HERC2 include
its involvement in DNA repair, DNA replication, and checkpoint control [21]. Apart from its role in
maintaining genome integrity, HERC2 can also function as a cell growth regulator. HERC2 is known
to modulate p53 activity by regulating its oligomerization. Depletion of HERC2 has been shown to
up-regulate cell growth and increase focus formation. Frameshift mutations of HERC2 have been
reported in gastric and colorectal cancer with microsatellite instability [21].
Consistent with the RNA-seq data, we also detected up-regulation of the BCL2 associated
athanogene 3 (BAG3) gene in both e-cig user and smoker (Figure 6). BAG3 belongs to a family of
co-chaperones characterized by a C-terminal BAG domain that binds the HSP70/HSPA ATPase domain,
and thus regulates the fate of HSP70 substrates. BAG3 is implicated in the regulation of a variety
of cellular processes, including apoptosis, development, cytoskeleton arrangement, and selective
macro-autophagy. BAG3 is thought to play a key role in the development of a wide variety of diseases,
including cancer [47]. Its binding partner, the heat shock protein 70 (HSPA1B), was also over-expressed
in the oral cells of e-cig users and smokers in this study (Figure 6). Protein phosphorylation is a
major regulatory mechanism of signal transduction cascades in eukaryotes, catalyzed by the reciprocal
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activity of protein kinases and phosphatases. We also analyzed the transcription status of the protein
phosphatase 1 regulatory inhibitor subunit 14C (PPP1R14C), a major inhibitor of the Ser/Thr protein
phosphatase-1 (PP-1) and confirmed that this gene was up-regulated in both e-cig users and smokers
(Figure 6). PPP1R14C plays a crucial role in multiple signal transduction pathways controlling cell cycle,
protein synthesis, neuronal activity, metabolism, and muscle contraction. Malfunction of these inhibitor
proteins has been linked to a variety of diseases, including cancer and cardiovascular disease [48].
Lastly, we acknowledge that our study population consisted of healthy adults of both genders
at different ages and of diverse races and ethnicities as well as other characteristics (see Table 1).
Given the relatively small size of our study population, matching all those characteristics in the three
groups of vapers, smokers, and controls would not have been feasible. For example, while smokers
were older than vapers, controls and vapers had a relatively similar age distribution. This is not
unexpected considering that e-cigs are a comparatively new tobacco product whereas combustible
cigarettes are not. Our catchment area for this and other ongoing studies on e-cigs and smoking
is the Greater Los Angeles Area, and our latest recruitment records among >2350 subjects show
consistently higher median age for smokers than vapers (ongoing work). We would like to, however,
stress that the differential gene-expression profile of vapers in the present study was established based
on comparison with controls (i.e., non-smokers non-vapers) whose median age was not statistically
significantly different from that of vapers. Currently, work in our laboratory is underway to expand
our investigations to large groups of e-cig users, smokers, and controls, whose relevant characteristics
are fully matched.
In summary, our whole transcriptome analysis of oral cells from exclusive e-cig users and smokers
shows that vapers, similarly to smokers, have deregulation of key genes, the majority of which
converging on cancer-related pathways and functions. The extent of gene deregulation and the
affected pathways in e-cig users are partly overlapping with, but mostly distinct from those of smokers.
Follow-up functional studies on the identified deregulated genes and associated pathways are currently
underway in our laboratory. To our knowledge, this is the first report to demonstrate that e-cig users
have significant deregulation of critically important genes and associated molecular pathways in the
oral epithelium, which is a major target tissue for smoking-associated cancer [16,17]. Our findings
warrant further investigations into the long-term effects of vaping not only in regular e-cig users but
also in non-users who are involuntarily exposed to secondhand e-cig vapor, e.g., children and fetuses
of vaping pregnant mothers. Evidence from research studies, such as the present one, can lay the
foundation for the development of scientifically based regulations on e-cig manufacturing, marketing,
and distribution.
4. Materials and Methods
4.1. Subject Recruitment and Enrollment
This study was conducted in accordance with the Declaration of Helsinki of 1975 (https://www.
wma.net/what-we-do/medical-ethics/declaration-of-helsinki/), revised in 2013. The study was
approved by Health Sciences Institutional Review Board of the University of Southern California
(HSIRB-USC), under the protocol number HS-16-00175 (Approval date: 4 April 2016). The study
was advertised in online forums, including Craigslist, Reddit, and myUSC (http://my.usc.edu), and
through social media (Twitter, Instagram, and Facebook). Also, flyers and leaflets were used to
advertise the study in local colleges, universities, and vape shops. Furthermore, an online survey
was developed, validated, and subsequently employed to solicit and query potential participants
(http://geteo.usc.edu). Individuals who appeared to have met the study criteria were contacted by
phone to complete a screening questionnaire. Based on the information obtained during the phone
screen, those who were deemed potentially eligible, were scheduled for an in-person visit to our
laboratory. During the visit, an expanded version of the phone screen was administered to reconfirm
eligibility, and informed consent was obtained, afterwards (see below).
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4.2. Inclusion and Exclusion Criteria for the Study
Eligible candidates for the study included healthy male or female adults of diverse races and
ethnicities who could read and write in English and understand and give informed consent. Health
indicators for exclusion were oral infection or inflammation, gum disease, dental decay, immune
system disorders, diabetes, respiratory diseases (e.g., asthma), kidney diseases, body mass index
<18 kg/m2 or >40 kg/m2, or any medical disorder/medication that could affect the subject’s safety
or study results. Any unstable or significant medical condition in the past 12 months, including but
not limited to symptomatic heart conditions, chronic obstructive pulmonary disease (COPD), stroke,
severe angina, and hypertension, was ground for exclusion. Being pregnant or having a baby in the
past 12 months was also exclusionary. Other exclusion criteria included uncontrolled mental illness or
substance abuse or inpatient treatment for those conditions in the past 12 months, use of recreational
or illicit drugs (e.g., marijuana or cocaine) in the past 6 months, and use of any medication known to
induce/inhibit CYP450 2A6 enzyme.
4.3. Personal Interview
Upon reconfirmation of the eligibility and obtaining informed consent, all participants underwent
a personal interview to provide detailed information about demographics, socio-economic status, use of
e-cigs, cigarettes, or other tobacco products; dietary habits, lifestyle, specifically, use of recreational/illicit
drugs, alcohol, and prescription or over-the-counter medicine; occupational and residential history
(specifically, secondhand smoke exposure); and family history of disease. Per request of one of the
reviewers, we confirm that, based on the questionnaire and in-person interview data, there was no
significant difference in secondhand smoke exposure among e-cig users, smokers, and controls.
4.4. Study Population
The study population consisted of healthy adults—both males and females of different races
and ethnicities, between the ages of 22 and 55 during the time of data collection—who resided in the
Greater Los Angeles Area. The lower age-limit was consistent with a new California law that bans
the sale of e-cigs and other tobacco products to anyone under the age of 21. The higher age-limit
was to ensure inclusion of a good range of participants, while avoiding the confounding effects of
advanced aging. The study population comprised of three groups: (I) exclusive e-cig users (n = 42),
(II) cigarette smokers only (n = 24), and (III) control non-smokers non-vapers (n = 27). We note that
differences in group size were taken into account during statistical analysis. Criteria for classification
of subjects, as e-cig users, cigarette smokers, or controls, were as follows: e-cig users were those who
reported current use of e-cigs for at least 3 times a week for a minimum of 6 months, and no use of
combustible cigarettes or any other tobacco products in the past 6 months. Smokers were those who
reported current smoking of tobacco cigarettes at least 3 times per week for a minimum of 1 year, and
no use of any other tobacco products, including e-cigs, in the past 6 months. Controls were those
who reported no use of any tobacco product (e-cigs or combustible) more than 5 times in their life
(lifetime consumption: fewer than 100 cigarettes or less than 5 vaping sessions), with no use in the past
6 months. Detailed characteristics of the study population are listed in Table 1.
4.5. Sampling and Processing of Oral Epithelial Cells
All subjects were required to refrain from eating, smoking, or vaping, at least, 1 h prior to visiting
our laboratory. Before sampling, subjects were asked to vigorously rinse their mouths with water to
remove saliva, residual food particles, and mucosal debris. An Ultra Soft Oral-B brush (SENSI.SOFT™;
Cincinnati, OH, USA) was placed in subject’s mouth, and sufficient pressure was applied to contact
the surface of the inside of his/her cheeks. Rotatory motion along the face and edge of the brush
was used to gently scrape the entire surface area of the inside of the cheek, while avoiding mouth
bleeding. The proximal, central, and distal regions of the inside of each cheek were brushed 15 times
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each. Once brushing of a region was completed, the brush was swirled in a tube pre-filled with 35 mL
ice-cold sterile phosphate buffer saline (PBS) to dislodge the cells from the bristles. Cycles of brushing
and washing the cells off of the bristles were repeated until all regions from both cheeks were sampled.
The two tubes containing the harvested cells from opposite cheeks were centrifuged at 800× g for
5 min at 4 ◦C. Pelleted cells from each tube were re-suspended in PBS, pooled into a single tube, and
re-centrifuged as above. The collected cell pellet was snap frozen and kept at −80 ◦C until further
analysis. In our preliminary studies, we have confirmed that this protocol provides ample number
of cells, the vast majority of which being intermediate and suparbasal oral epithelial cells. To rule
out significant contamination by other cell types, we have also performed differential cell count on
the collected oral cells and verified the overwhelming presence of oral epithelial cells in all samples.
To avoid any potential bias, sample collection and processing of the collected specimens from different
groups were done in variable orders, not in batches, and in a “blind” fashion.
4.6. Sampling of Peripheral Blood
To verify the vaping/smoking status of the study participants, peripheral blood (30 mL) was
collected by venipuncture, and plasma cotinine was measured, as described below. Plasma fraction
was collected by centrifugation, and erythrocytes and granulocytes, lymphocytes, and peripheral
mononuclear cells were further separated using the Leucosep™ tubes according to the manufacturer’s
instructions (Greiner Bio-One Inc., Monroe, NC, USA). The collected plasma was snap frozen and
preserved at −80 ◦C until further analysis.
4.7. RNA-Seq Analysis
Total RNA was isolated from snap frozen oral epithelial cells using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). The isolated RNA samples were checked for quality control using the RNA
6000 Nano Chip kit in an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Libraries for RNA-seq were prepared from total RNA (300 ng per sample) using the Kapa Hyper
Prep Kits with RiboErase (Kapa Biosystems, Wilmington, DE, USA). The workflow consisted of rRNA
depletion, cDNA generation, and end repair to generate blunt ends, A-tailing, adaptor ligation, and
PCR amplification. Different adaptors were used for multiplexing samples in one lane. Sequencing
was performed on Illumina Nextseq500 for a single-end read for 75 cycles. Data quality check was
done on Illumina SAV. Demultiplexing was performed with Illumina Bcl2fastq2 v2.17 program. To rule
out any potential bias, library construction and data acquisition for samples from different groups
(vapers, smokers, and controls) were done in the same run, not in different batches, and in a “blind”
fashion. Detailed descriptions of data processing and analysis are provided in Supplementary Data.
The RNA-seq data will be deposited in the Gene Expression Omnibus database at NCBI (htttp://www.
ncbi.nlm.nih.gov/geo/), and accession number will be provided as soon as it becomes available.
4.8. Gene Ontology and Canonical Pathways Analyses
Gene ontology (GO) analysis was performed using a combination of the Database for Annotation,
Visualization and Integrated Discovery (DAVID) Bioinformatics Tool v.6.8 [49] and the Ingenuity®
Pathway Analysis (IPA®) v.9 tool (QIAGEN Bioinformatics, Redwood City, CA, USA; www.ingenuity.
com). The Functional Clustering Analysis tool in DAVID was used to group together redundant
GO categories and other types of functional terms (e.g., pathway, disease, etc.), while functional
identification of gene networks, canonical pathways, and upstream regulators was done by IPA®.
4.9. Reverse Transcription Quantitative PCR (RT-qPCR)
To validate the RNA-seq data, we used our published RT-qPCR protocol with a few
modifications [50] to determine the expression level of individual up-regulated or down-regulated
genes identified by sequencing analysis. Briefly, total RNA (0.1–0.2 micrograms or µg) isolated
from oral epithelial cell samples was reverse transcribed into cDNA using the iScript™ Reverse
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Transcription Supermix for RT-qPCR (iScript RT Supermix) (Bio-Rad laboratories, Inc., Hercules, CA,
USA). The synthesized cDNA (20 ng) was pre-amplified for 12 cycles using a pool of custom-made
primers and the SsoAdvanced™ PreAmp Supermix, according to manufacturer’s instructions (Bio-Rad
laboratories, Inc.). The completed pre-amplification reaction was then diluted 1:10 with TE buffer
(10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0) and 2 microlites or µL of pre-amplified diluted cDNA
was used per reaction in the presence of gene-specific primers and SsoAdvanced™ Universal SYBR®
Green Supermix (Bio-Rad laboratories, Inc.). The human TATA-binding protein (TBP) gene was used
as a reference. All PCR reactions were carried out using the CFX96 Touch™ Real-Time PCR detection
system (Bio-Rad Laboratories, Inc.). The cycling conditions included a pre-incubation at 95 ◦C for
2 min, followed by 40 cycles at 95 ◦C for 5 s and 58 ◦C for 30 s. All reactions (5 samples per group)
were performed in triplicate for a total of 15 reactions per biological set. Fold-changes in transcript
levels were calculated in the biological sets (e.g., e-cig users and smokers versus controls) using the
Bio-Rad CFX Maestro™ software (Bio-Rad laboratories, Inc.). The primer sets used for RT-qPCR are
available upon request.
4.10. Cotinine Measurement
Plasma cotinine was measured by a solid phase competitive enzyme-linked immunosorbent assay
(ELISA), as described in Supplementary Data.
4.11. Measurement of Carbon Monoxide in Breath and Determination of %Carboxyhemoglobin
Carbon monoxide (CO) levels in exhaled breath and percentage of carboxyhemoglobin (%COHb)
were determined using a Bedfont Micro+TM Smokerlyzer® Breath CO monitor, according to the
instructions of the manufacturer (Bedfont Scientific Ltd., Kent, UK).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/3/
738/s1. Table S1: Compiled list of aberrantly expressed transcripts and associated genomic loci (if annotated) in
the e-cig users versus controls. Table S2: Compiled list of aberrantly expressed transcripts and associated genomic
loci (if annotated) in cigarette smokers versus controls. Table S3: Relevant diseases identified by DAVID in e-cig
users. Figure S1: Comparison of the upstream regulators affected in both e-cig users and smokers relative to
controls by IPA®. Figure S2: Visualization of the network of deregulated genes converging on TP53 gene in e-cig
users and smokers relative to controls by IPA®.
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